Assam and Arunachal Pradesh are among 30 states and union territories in India which has been witnessing the lowest fatality rate due to the COVID-19 pandemic, union ministry of Health and Family Welfare said on Tuesday.
As per health minister statistics, Assam has registered 0.25 per cent case fatality rate and Arunachal Pradesh registered 0.19 percent which is the lowest in comparison to the national average of 1.92 per cent.
Ready for a challenge? Click here to take our quiz and show off your knowledge!
Health Ministry statistics said that Assam has 22736 active Covid cases till date whereas 197 people have already died. Accordingly, Arunachal Pradesh has 843 total active cases five people have died so far.
India on the day has set another record in COVID-19 tests conducted per day.
Nearly 9 lakh (8,99,864) tests have been conducted in a single day, taking the total number to 3,09,41,264.
Ready for a challenge? Click here to take our quiz and show off your knowledge!
“Even with such a high level of testing, the positivity has remained low i.e. 8.81 percent compared to the weekly national average i.e. 8.84 percent. Test, track and treatment are behind such a good trend,” the health ministry said.
India has also recorded the highest single day recoveries of 57,937 in the last 24 hours.
This is higher than the confirmed cases added during the same period (55,079).
With more patients recovering and being discharged from hospitals and home isolation (in case of mild and moderate cases), the total recoveries have reached nearly 20 lakhs (19,77,779).
With this the gap between the recovered patients and the active cases has crossed 13 lakhs on Wednesday.
India’s recovery rate touches 73.18 per cent.
Meanwhile, Dr V K Paul, member in Niti Aayog has said that the phase I and II human clinical trials of two indigenous COVID-19 vaccines are progressing well.
“The third vaccine (Oxford vaccine) will start the phase III of human clinical trials from Wednesday,” said Paul.
Bharat Biotech and Ahamedabad based Zydus Cadila have been conducting the Phase I and II trial of indeginious COVID-19 vaccine.